COX‐1 Inhibitors: Beyond Structure Toward Therapy. Issue 4 (25th April 2016)

• Record Type: Journal Article
• Authors: Vitale, Paola; Panella, Andrea; Scilimati, Antonio; Perrone, Maria Grazia
• Is Part Of: Medicinal research reviews. Volume 36:Issue 4(2016:Jul.)
• Page Start: 641
• Page End: 671
• Publication Date: 2016-04-25
• Subjects: COX‐1 inhibitors -- natural compounds and dietary phytochemicals -- docking studies -- neuroinflammation -- ovarian cancer; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; 615
• DOI: 10.1002/med.21389
• Languages: English
• ISSNs: 0198-6325

Abstract

Abstract: Biosynthesis of prostaglandins from arachidonic acid (AA) is catalyzed by cyclooxygenase (COX), which exists as COX‐1 and COX‐2. AA is in turn released from the cell membrane upon neopathological stimuli. COX inhibitors interfere in this catalytic and disease onset process. The recent prominent discovery involvements of COX‐1 are mainly in cancer and inflammation. Five classes of COX‐1 inhibitors are known up to now and this classification is based on chemical features of both synthetic compounds and substances from natural sources. Physicochemical interactions identification between such molecules and COX‐1 active site was achieved through X‐ray, mutagenesis experiments, specific assays and docking investigations, as well as through a pharmacometric predictive model building. All these insights allowed the design of new highly selective COX‐1 inhibitors to be tested into those disease models in which COX‐1 is involved. Particularly, COX‐1 is expressed at high levels in the early to advanced stages of human epithelial ovarian cancer, and it also seems to play a pivotal role in cancer progression. The refinement of COX‐1 selective inhibitor structure has progressed to the stage that some of the inhibitors described in this review could be considered as promising active principle ingredients of drugs and hence part of specific therapeutic protocols. This review aims to outline achievements, in the last 5 years, dealing with the identification of highly selective synthetic and from plant extracts COX‐1 inhibitors and their theranostic use in neuroinflammation and ovarian cancer. Their gastrotoxic effect is also discussed.